MacroGenics Balance Sheet Health
Financial Health criteria checks 6/6
MacroGenics has a total shareholder equity of $106.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $248.3M and $142.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$184.24m |
| Equity | US$106.15m |
| Total liabilities | US$142.13m |
| Total assets | US$248.29m |
Recent financial health updates
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25
Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21Recent updates
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21MacroGenics: Revisiting Our Pipeline And Investment Analysis
Aug 10MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be
Aug 03MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology
Jun 16Financial Position Analysis
Short Term Liabilities: MGNX's short term assets ($202.6M) exceed its short term liabilities ($55.8M).
Long Term Liabilities: MGNX's short term assets ($202.6M) exceed its long term liabilities ($86.4M).
Debt to Equity History and Analysis
Debt Level: MGNX is debt free.
Reducing Debt: MGNX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGNX has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 3.6% each year.